Research map: Integrated plasma proteomics identifies HLA-G and osteopontin as circulating biomarkers of resistance to PD-1 inhibitor plus chemotherapy in choriocarcinoma

Back to the article

Papers in this map

  1. The Cancer Genome Atlas Pan-Cancer analysis project · John N. Weinstein · 2013 · 9868 citations · Cited by this paper
  2. A review of soluble mediator and cytokine networks linking combination immunotherapy, tumor microenvironment remodeling and skeletal muscle dysfunction · 2026 · Related
  3. Macrophages as regulators of tumour immunity and immunotherapy · David Glenn DeNardo · 2019 · 2675 citations · Cited by this paper
  4. GFI1 as a novel regulator of γδ T cell development and the IL-17/IFN-γ lineage commitment · 2026 · Related
  5. TISIDB: an integrated repository portal for tumor–immune system interactions · Beibei Ru · 2019 · 2667 citations · Cited by this paper
  6. HIF-1α-centered metabolic reprogramming in osteoarthritis: cell type-specific effects and intercellular crosstalk among chondrocytes, BMSCs, and macrophages · 2026 · Related
  7. An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion · John David Klement · 2018 · 396 citations · Cited by this paper
  8. Acquired immune-mediated thrombotic thrombocytopenic purpura with severe cholestatic liver injury and reversible acute kidney injury after ivonescimab-containing chemoimmunotherapy: a case report and literature review · 2026 · Related
  9. Soluble HLA‐A,‐B,‐C and ‐G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation · Paola Contini · 2002 · 358 citations · Cited by this paper
  10. Lipoprotein (a) fuels EV71 replication by activating p38 MAPK-autophagy axis · 2026 · Related
  11. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes · Frédérique‐Anne Le Gal · 1999 · 316 citations · Cited by this paper
  12. Delivery platforms for in vivo CAR-T engineering · 2026 · Related
  13. Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation · Georg F. Weber · 2002 · 279 citations · Cited by this paper
  14. Envafolimab – novel anti-PD-1/PD-L1 antibody in cancer treatment · 2026 · Related
  15. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia · Ehsan Ghorani · 2017 · 218 citations · Cited by this paper
  16. Contribution of monocyte subpopulations to the pathogenesis and therapy outcome of type 1 diabetes management in pediatric patients · 2026 · Related
  17. Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy · Eric Huttenlocher Bent · 2021 · 160 citations · Cited by this paper
  18. Germline based SARS-CoV-2 specific B cell repertoire motif identified with novel sequence based bioinformatic pipeline · 2026 · Related
  19. Spatial and single-cell transcriptomics decipher the cellular environment containing HLA-G+ cancer cells and SPP1+ macrophages in colorectal cancer · Yuki Ozato · 2023 · 142 citations · Cited by this paper
  20. Defining nature, responses and drivers of regulatory- and conventional CD4+ T cells in the human term decidua · 2026 · Related
  21. Characterization of a TiO2 enrichment method for label-free quantitative phosphoproteomics · Alex Montoya · 2011 · 118 citations · Cited by this paper
  22. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1 · Sarah Ann Weiss · 2021 · 102 citations · Cited by this paper
  23. PD-L1 Expression in Premalignant and Malignant Trophoblasts From Gestational Trophoblastic Diseases Is Ubiquitous and Independent of Clinical Outcomes · Pierre‐Adrien Bolze · 2017 · 99 citations · Cited by this paper
  24. PD‐L1, B7‐H3 and VISTA are highly expressed in gestational trophoblastic neoplasia · Liju Zong · 2019 · 99 citations · Cited by this paper
  25. The Role of Osteopontin in Tumor Progression Through Tumor-Associated Macrophages · Yuying Tan · 2022 · 95 citations · Cited by this paper
  26. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial · Hongyan Cheng · 2021 · 87 citations · Cited by this paper
  27. Osteopontin controls immunosuppression in the tumor microenvironment · Michael R. Shurin · 2018 · 72 citations · Cited by this paper
  28. SPP1 represents a therapeutic target that promotes the progression of oesophageal squamous cell carcinoma by driving M2 macrophage infiltration · Chen Wang · 2024 · 72 citations · Cited by this paper
  29. First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors · Lillian L. Siu · 2021 · 71 citations · Cited by this paper
  30. HLA-G/LILRBs: A Cancer Immunotherapy Challenge · Edgardo Delfino Carosella · 2021 · 62 citations · Cited by this paper
  31. Diagnosis and management of gestational trophoblastic disease: 2025 update · Hys Ngan · 2025 · 56 citations · Cited by this paper
  32. Effective anti-programmed cell death 1 treatment for chemoresistant gestational trophoblastic neoplasia · Min Chul Choi · 2019 · 55 citations · Cited by this paper
  33. The Role of HLA-G in Tumor Escape: Manipulating the Phenotype and Function of Immune Cells · Lu Liu · 2020 · 54 citations · Cited by this paper
  34. How Chemotherapy Affects the Tumor Immune Microenvironment: A Narrative Review · Marco Carlo Merlano · 2022 · 49 citations · Cited by this paper
  35. Targeting SPP1+ macrophages via the SPP1-CD44 axis reveals a key mechanism of immune suppression and tumor progression in ovarian cancer · Lisha Hou · 2025 · 49 citations · Cited by this paper
  36. Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD)–European Society of Gynaecologic Oncology (ESGO)–Gynecologic Cancer InterGroup (GCIG)–International Society for the Study of Trophoblastic Diseases (ISSTD) · Christianne A. R. Lok · 2025 · 46 citations · Cited by this paper
  37. Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects · Siyuan Wang · 2024 · 44 citations · Cited by this paper
  38. Gestationally dependent immune organization at the maternal-fetal interface · Amber R. Moore · 2022 · 37 citations · Cited by this paper
  39. The Molecular Mechanisms of HLA-G Regulatory Function on Immune Cells during Early Pregnancy · Jia Mao · 2023 · 35 citations · Cited by this paper

Source: OpenAlex (CC0)